Genomic Health Inc's Cash & cash equivalent grew by 13.09 % in the Q3 2019 sequentially, faster than Current Liabilities, this led to improvement in Genomic Health Inc's Quick Ratio to 4.76, above Genomic Health Inc average Quick Ratio.

Within Medical Laboratories industry 10 other companies have achieved higher Quick Ratio than Genomic Health Inc in third quarter 2019. While Quick Ratio total ranking has improved so far during the Q3 2019 to 678, from total ranking in the second quarter 2019 at 705.

Explain Quick Ratio?
How much Cash & cash equivalents GHDX�s has?
What are GHDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GHDX Quick Ratio	(Sep 30 2019) Q3	(Jun 30 2019) Q2	(Mar 31 2019) Q1	(Dec 31 2018) Q4	(Sep 30 2018) Q3
Y / Y Current Liabilities Change	14.87 %	35.95 %	28.04 %	67.47 %	13.47 %
Y / Y Cash & cash equivalent Change	50.29 %	59.24 %	57.96 %	61.91 %	54.05 %
Quick Ratio MRQ	4.76	4.48	4.16	3.17	3.64
GHDX's Total Ranking	# 678	# 705	# 582	# 846	# 820
Seq. Current Liabilities Change	6.5 %	9.86 %	-25.22 %	31.29 %	26.05 %
Seq. Cash & cash equivalent Change	13.09 %	18.25 %	-1.83 %	14.48 %	19.82 %

Quick Ratio third quarter 2019 Company Ranking
Within:	No.
Medical Laboratories Industry	# 11
Healthcare Sector	# 335
Overall Market	# 678

Quick Ratio Statistics
High	Average	Low
5.73	3.6	2.35
(Sep 30 2012)		(Dec 31 2015)

Financial Statements
Genomic Health Inc's Current Liabilities	$ 58 Millions	Visit GHDX's Balance sheet
Genomic Health Inc's Cash & cash equivalent	$ 275 Millions	Visit GHDX's Balance sheet
Source of GHDX's Sales		Visit GHDX's Sales by Geography

Cumulative Genomic Health Inc's Quick Ratio

GHDX's Quick Ratio for the trailling 12 Months

GHDX Quick Ratio	(Sep 30 2019) 12 Months	(Jun 30 2019) 12 Months	(Mar 31 2019) 12 Months	(Dec 31 2018) 12 Months	(Sep 30 2018) 12 Months
Y / Y Current Liabilities TTM Growth	35.22 %	35.59 %	27.45 %	22.17 %	3.08 %
Y / Y Cash & cash equivalent TTM Growth	56.79 %	58.42 %	53.86 %	49.39 %	41.89 %
Quick Ratio TTM	4.1	3.82	3.65	3.46	3.54
Total Ranking TTM	# 4385	# 4419	# 367	# 4409	# 550
Seq. Current Liabilities TTM Growth	3.4 %	6.98 %	5.55 %	15.82 %	3.68 %
Seq. Cash & cash equivalent TTM Growth	10.94 %	12.05 %	11.17 %	13.46 %	12.09 %

Quick ratio ranking by company, industry and sector >> Back to GHDX Financial Strength Comparisons >> Go to Compare GHDX Quick Ratio to its Competitors

On the trailing twelve months basis GHDX Cash & cash equivalent soared by 50.29 % in Q3 2019 year on year, faster than Current Liabilities, this led to increase in in Genomic Health Inc's Quick Ratio to 4.1, above GHDX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 35 other companies have achieved higher Quick Ratio than Genomic Health Inc. While Quick Ratio overall ranking has improved so far to 4385, from total ranking during the twelve months ending second quarter 2019 at 4419.

Explain Quick Ratio?
How much Cash & cash equivalents GHDX�s has?
What are GHDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 36
Healthcare Sector	# 863
Within the Market	# 4385

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.22	3.07	2.29
(Sep 30 2019)		(Jun 30 2016)

Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Medical Laboratories Industry	Quick Ratio	Sep 30 2019 MRQ Cash & cash equivalent	Sep 30 2019 MRQ Current Liabilities
Evolutionary Genomics Inc	13.01	$ 0.254 Millions	$ 0.020 Millions
Veracyte Inc	12.77	$ 195.662 Millions	$ 15.328 Millions
Castle Biosciences Inc	10.23	$ 94.500 Millions	$ 9.238 Millions
Exagen Inc	10.16	$ 77.828 Millions	$ 7.662 Millions
Personalis Inc	9.32	$ 127.276 Millions	$ 13.663 Millions
Guardant Health Inc	7.71	$ 522.956 Millions	$ 67.817 Millions
Fulgent Genetics Inc	7.55	$ 32.118 Millions	$ 4.253 Millions
Invitae Corporation	6.78	$ 467.312 Millions	$ 68.936 Millions
Dermtech Inc	5.75	$ 21.437 Millions	$ 3.731 Millions
Genomic Health Inc	4.76	$ 275.435 Millions	$ 57.900 Millions
Incyte Corporation	4.30	$ 1,986.218 Millions	$ 461.683 Millions
Natera Inc	3.50	$ 238.364 Millions	$ 68.059 Millions
Miragen Therapeutics Inc	3.26	$ 33.838 Millions	$ 10.385 Millions
Check Cap Ltd	2.74	$ 7.685 Millions	$ 2.802 Millions
Lightwave Logic Inc	2.49	$ 2.168 Millions	$ 0.872 Millions
Exact Sciences Corporation	2.42	$ 1,160.545 Millions	$ 479.524 Millions
Psychemedics Corporation	1.85	$ 6.492 Millions	$ 3.515 Millions
Luna Innovations Inc	1.74	$ 21.414 Millions	$ 12.332 Millions
Caredx Inc	1.32	$ 40.927 Millions	$ 30.971 Millions
Biocept Inc	1.13	$ 6.539 Millions	$ 5.783 Millions

Date modified: 2026-09-26T07:02:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.